Jemperli, Zynlonta require prior authorization for dates of service on or after July 26 for most members

For dates of service on or after July 26, 2021, we’re adding prior authorization requirements for the following drugs covered under the medical benefit:

• Jemperli™ (dostarlimab‑gxly), HCPCS codes J3490, J3590, J9999, C9399
• Zynlonta™ (loncastuximab tesirine‑lpyl), HCPCS codes J3490, J3590, J9999, C9399

Submit prior authorization requests through AIM Specialty Health^®.

Prior authorization requirements apply when these drugs are administered in outpatient settings for:

• Blue Cross Blue Shield of Michigan commercial members who have coverage through fully insured groups and members with individual coverage

Exceptions: The Blue Cross commercial requirements don’t apply to members who have coverage through the Michigan Education Special Services Association or the Blue Cross and Blue Shield Federal Employee Program^®, or to UAW Retiree Medical Benefits Trust non-Medicare members.

• Medicare Plus Blue℠
• Blue Care Network commercial
• BCN Advantage℠

How to submit authorization requests
Submit authorization requests to AIM using one of the following methods:

• Through the AIM ProviderPortal**
• By calling the AIM Contact Center at 1‑844‑377‑1278

More about authorization requirements
Authorization isn’t a guarantee of payment. As always, health care practitioners need to verify eligibility and benefits for members.

For additional information on requirements related to drugs covered under the medical benefit, see:

• Blue Cross commercial and BCN commercial:
• Medical oncology prior authorization list for Blue Cross commercial fully insured and BCN commercial members
• Blue Cross and BCN utilization management medical drug list
• Medicare Advantage:
• Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue and BCN Advantage members

We’ll update the appropriate drug lists to reflect the information in this message prior to the effective date.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.